Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition which is used for treating leukemia and contains idelalisi and application

A compound composition and the technology of the composition, applied in the field of medicine, can solve the problems of short drug exposure time, limited effectiveness data, short response duration, etc., and achieve the effects of clear components, reduced dosage, and growth inhibition.

Active Publication Date: 2016-03-09
张陆军
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

By lymphoma type, key efficacy endpoints were as follows: For patients with follicular lymphoma, ORR was 54% (39 of 72 patients responded), median DOR was not estimable, and median follow-up time was 8.1 months; for patients with small lymphocytic lymphoma, the ORR was 58% (15 of 26 patients responded), and the median DOR was 11.9 months; while for FL and SLL populations, due to the relatively short duration of drug exposure, Response duration was also short, resulting in limited efficacy data

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition which is used for treating leukemia and contains idelalisi and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1 The inhibitory effect of the pharmaceutical composition of the present invention on leukemia cell lines

[0020] Human acute promyelocytic leukemia NK4 cells, chronic myeloid leukemia K562 cells, and retinoic acid-resistant promyelocytic leukemia MR-2 cells were respectively inoculated in RPMI-1640 culture medium at 37°C containing 5% CO 2 Cultured and subcultured in the incubator, inoculated in 96-well culture plate, added the corresponding concentration of drugs according to the group during inoculation, paralleled 5 wells for each concentration, measured the tumor growth inhibition rate by MTT reduction reaction after 48 hours, and used the Excel system for statistical analysis of the test data For analysis, see Table 1 for specific test results.

[0021] The test groups and the final concentration of administration are as follows:

[0022] Blank control group: equal volume of excipient

[0023] Idelani group A: 2.4mg / mL Idelani

[0024] Adranib group...

Embodiment 2

[0035] Embodiment 2 The therapeutic effect of the pharmaceutical composition of the present invention on leukemia model mice

[0036] Thirty Kunming male mice weighing 18-22 g (purchased from Tianjin Institute of Hematology) were subcutaneously injected with L615K lymphocytic leukemia cells (purchased from Tianjin Institute of Hematology) to form tumor-bearing mouse models. All mice were divided into 6 groups, 5 in each group, and each group was given the following therapeutic drugs:

[0037]Blank control group: equal volume of excipient

[0038] Idelani group A: 2.5mg / kg Idelani

[0039] Idelani group B: 5mg / kg Idelani

[0040] Catalpol A group: 10mg / kg catalpol

[0041] Catalpol B group: 20mg / kg catalpol

[0042] Composition group A: 2.5mg / kg ideranib+10mg / kg catalpol

[0043] Composition B group: 2.5mg / kg ideranib+20mg / kg catalpol

[0044] Composition C group: 10mg / mL Idrani+10mg / mL catalpol

[0045] All the administration groups were intragastrically administered an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine composition which is used for treating leukemia and contains idelalisi and application, belongs to the medical field and provides the medicine drug containing idelalisi in order to reduce the toxic and side effects of existing leukemia treating medicine of idelalisi and further enhance the treatment effect of idelalisi on leukemia. By means of the medicine composition, growth of acute promyelocytic leukemia NK4 cells, chronic myelogenous leukemia K562 cells and retinoic-acid-resistant promyelocytic leukemia MR-2 cells of a person can be remarkably reduced, and active components of two kinds of medicine have a remarkable synergistic effect on treating leukemia. The medicine composition has the advantages that the components are clear, the toxic and side effects are small, and the treatment effect is good, and the medicine composition is suitable for being popularized clinically and used for treating leukemia.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for treating leukemia and its application. Background technique [0002] At present, cancer is one of the major diseases that seriously affect human health and threaten human life. Together with cardiovascular and cerebrovascular diseases and accidents, cancer constitutes the top three causes of death in all countries in the world today. Therefore, the World Health Organization and the health departments of governments of various countries have listed conquering cancer as a top priority. There are three main ways to treat leukemia in the world. One is to use surgical resection to remove the diseased tissue to prevent the spread of cancer cells; but to use chemotherapy or radiotherapy to kill cancer cells; the third is to use drugs to treat it. Adopt the method for surgical excision to increase patient's misery, hurt its vitality, and expense is h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P35/02A61K31/522
Inventor 张陆军程浩汪电雷赵宜惠谈青时云龙靳志红张恒志
Owner 张陆军
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com